Shionogi-ViiV's dolutegravir non-inferior to raltegravir in treatment-naïve HIV patients
This article was originally published in Scrip
Executive Summary
Shionogi and ViiV Healthcare have released preliminary Phase III results for dolutegravir (S/GSK1349572), showing that the HIV integrase inhibitor met its primary endpoint of non-inferiority to raltegravir (Merck & Co's Isentress) in treatment-naïve patients with HIV-1.